Friday, 19 July 2019

Glenmark receives ANDA approval for Ezetimibe and Simvastatin Tablets

28 June 2019 | News

It is a generic version of Vytorin Tablets

Glenmark Pharmaceuticals has been granted final approval by the USFDA for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, a generic version of Vytorin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, of MSD International GmbH.

According to IQVIATM sales data for the 12 month period ending April 2019, the Vytorin® Tablets market2 achieved annual sales of approximately $92.4 million.

Glenmark’s current portfolio consists of 157 products authorized for distribution in the U.S. marketplace and 58 ANDA’s pending approval with the USFDA.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls